Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baird Medical Investment HoldingsBDMD -2.86%17 Return-on-Tangible-Equity is -95.69% as of Dec. 2025. GuruFocus rates BDMD with a GF Score™ of 17/100. The stock has 7 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Baird Medical Investment Holdings ranks worse than 84.98% on this metric.
The historical rank and industry rank for Baird Medical Investment Holdings's Return-on-Tangible-Equity or its related term are showing as below:
BDMD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -76.97 Med: 34.3 Max: 66.17
Current: -76.91
During the past 5 years, Baird Medical Investment Holdings's highest Return-on-Tangible-Equity was 66.17%. The lowest was -76.97%. And the median was 34.30%.
BDMD's Return-on-Tangible-Equity is ranked worse than 84.98% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs BDMD: -76.91
Baird Medical Investment Holdings (NAS:BDMD) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Baird Medical Investment Holdings Return-on-Tangible-Equity Related Terms
Baird Medical Investment Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baird Medical Investment Holdings Return-on-Tangible-Equity Chart
Baird Medical Investment Holdings Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Return-on-Tangible-Equity
66.17
61.21
34.30
33.10
-76.97
Baird Medical Investment Holdings Semi-Annual Data
BDMD vs TELA, NSPR, PAVM: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Baird Medical Investment Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baird Medical Investment Holdings Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baird Medical Investment Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Baird Medical Investment Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -95.69% mean?
Baird Medical Investment Holdings (BDMD) has a Return-on-Tangible-Equity of -95.69% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Baird Medical Investment Holdings and its competitors. According to the industry distribution chart, Baird Medical Investment Holdings ranks #645 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Baird Medical Investment Holdings' Return-on-Tangible-Equity too high?
Baird Medical Investment Holdings' current Return-on-Tangible-Equity is -95.69%. Based on the distribution chart, Baird Medical Investment Holdings ranks #645 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Baird Medical Investment Holdings has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Baird Medical Investment Holdings' Return-on-Tangible-Equity compare to TELA and NSPR?
According to the Medical Devices & Instruments industry distribution chart, Baird Medical Investment Holdings ranks #645 out of 759 companies for Return-on-Tangible-Equity. This places Baird Medical Investment Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Baird Medical Investment Holdings and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baird Medical Investment Holdings's current Return-on-Tangible-Equity is -95.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baird Medical Investment Holdings stock overvalued right now?
Baird Medical Investment Holdings (BDMD) has a current Return-on-Tangible-Equity of -95.69%. The current Return-on-Tangible-Equity is -95.69%. Baird Medical Investment Holdings' overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Baird Medical Investment Holdings (BDMD), the current Return-on-Tangible-Equity is -95.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Baird Medical Investment Holdings Business Description
Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China. The company combines clinical expertise with technologies to develop non-invasive treatment solutions. Its proprietary MWA medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Its core activities include the development and commercialization of thyroid microwave ablation systems and an active R&D pipeline of AI-integrated robotic systems, integrating hardware, software, and system-based solutions.
17GF Score
Get the complete analysis for BDMD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDMD has been successfully added to your 
